Current therapies targeting albuminuria in diabetic nephropathy leave residual urinary
albumin secretion, which meanwhile leave residual cardiovascular risk. Previous studies
demonstrated that sulodexide could reduce albuminuria in type 2 diabetic patients. But no
data concerning Chinese population is available. The investigators aim to provide evidence of
effects of sulodexide on diabetic nephropathy in Chinese diabetic patients. Further the
investigators also test the hypothesis that sequential administration of intravenous and oral
replacement of the drug would gain an earlier and greater reduction of albuminuria, compared
with oral use only.